Treatment for human coronavirus infection
AssigneeThe Administrators of the Tulane Educational Fund
InventorGregory Jaye Bix
Life of this patent
Estimating the term…
Abstract
Treating a human coronavirus (hCoV) infection includes administering an effective amount of an inhibitor of an α5- or αv-containing integrin to a subject in need thereof. The integrin inhibitor can be ATN-161. The hCoV can be SARS-CoV or SARS-CoV-2.
Claims25
A method of treating a human coronavirus (hCoV) infection, comprising administering an effective amount of an integrin inhibitor of an α5- or αv-containing integrin to a subject in need thereof.
5-6. (canceled)
11-12. (canceled)
15-19. (canceled)
The method of claim 18, wherein the subject has at least one symptom of SARS or COVID.
21-23. (canceled)
A pharmaceutical composition for use in the treatment of a human coronavirus (hCoV) infection, comprising an integrin inhibitor of an α5- or αv-containing integrin and a pharmaceutically-acceptable carrier.
33-58. (canceled)
Dependencies are inferred from the claim text.